OTX-101 0.09%
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Keratoconjunctivitis Sicca
Conditions
Keratoconjunctivitis Sicca
Trial Timeline
Jul 29, 2016 → Aug 15, 2017
NCT ID
NCT02845674About OTX-101 0.09%
OTX-101 0.09% is a phase 3 stage product being developed by Sun Pharmaceutical for Keratoconjunctivitis Sicca. The current trial status is completed. This product is registered under clinical trial identifier NCT02845674. Target conditions include Keratoconjunctivitis Sicca.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02845674 | Phase 3 | Completed |
Competing Products
15 competing products in Keratoconjunctivitis Sicca
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| FK506 | Astellas Pharma | Phase 3 | 77 |
| FK506 + placebo | Astellas Pharma | Phase 3 | 77 |
| OTX-101 0.05% + OTX-101 0.09% + Vehicle | Sun Pharmaceutical | Phase 2/3 | 65 |
| cyclosporine + vehicle of OTX-101 | Sun Pharmaceutical | Phase 3 | 77 |
| INS365 Ophthalmic Solution | Merck | Phase 3 | 77 |
| Pimecrolimus + Vehicle | Novartis | Phase 2 | 52 |
| Cyclosporine A + Dexamethasone | Novartis | Approved | 85 |
| Rebamipide | Novartis | Phase 3 | 77 |
| Rebamipide | Novartis | Phase 3 | 77 |
| Tasocitinib + Tasocitinib + vehicle for Tasocitinib | Pfizer | Phase 2 | 51 |
| Dupilumab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + Placebo | Rigel Pharmaceuticals | Phase 1 | 25 |
| R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + Placebo | Rigel Pharmaceuticals | Phase 2 | 44 |
| CF101 | Can Fite Biopharma | Phase 3 | 69 |
| CF101 + Placebo | Can Fite Biopharma | Phase 2 | 44 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85